Publication
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerLung Adenocarcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR L858Rcivic_curation1.00
Curated evidence
Evidence citing this paper (6)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27032107
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR E746_A750del1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4207In a retrospective study of 46 advanced non-small cell lung cancer patients, two patients harboring EGFR E746_A750del mutation were associated with resistance to erlotinib treatment. One patient survi… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC | civic |
| EGFR G719A1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4196In a retrospective study of 46, Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR G719A mutation was associated with resistance to erlotinib treatment. The patient survived 9.… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC | civic |
| EGFR L747_P753delinsS1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4270In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L747_P753insS mutation was associated with resistance to erlotinib treatment. The patient surv… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC | civic |
| EGFR L858R1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID4290In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 mon… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC | civic |
| EGFR N771delinsVH1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | — | submitted | EID4796In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR N771insVH mutation was associated with resistance to erlotinib treatment. The patient survived… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC | civic |
| EGFR S768_D770dup1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | — | submitted | EID4490In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR S768_D770insSVD mutation was associated with resistance to erlotinib treatment. The patient su… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC | civic |